GlassScriptPhysician profile
William P Rusche
NPI 1134202880
$10,194.36
in general payments reported to CMS, 2019-2025
41 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $893 · 2021: $929 · 2022: $2,894 · 2023: $1,606 · 2024: $1,101 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,880 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,879.74 |
| Education | $264.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,279.12 | 2019-2025 | |
| Abbvie INC. | $1,891.97 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,363.95 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Janssen Biotech, INC. | $908.01 | 2019-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $395.39 | 2019-2025 | |
| Ucb, INC. | $233.52 | 2021-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $225.84 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $189.00 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $182.54 | 2022-2024 | Acthar |
| Lilly USA, LLC | $152.40 | 2019-2025 | Taltz |
| Regeneron Healthcare Solutions, INC. | $118.20 | 2019-2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $116.88 | 2021-2025 | Saphnelo, Farxiga |
| Genzyme Corporation | $104.11 | 2020 | |
| Ani Pharmaceuticals, INC. | $103.74 | 2022-2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $94.52 | 2025 | Ozempic, Rybelsus |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rusche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.